» Articles » PMID: 35158823

Spine Metastases in Immunocompromised Mice After Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Feb 15
PMID 35158823
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer cells frequently metastasize to bone, where their interaction with bone remodeling cell types enhances osteolytic bone destruction. Importantly, however, whereas skeletal analyses of xenograft models are usually restricted to hindlimb bones, human skeletal metastases are far more frequent in the spine, where trabecular bone mass is higher compared to femur or tibia. Here, we addressed whether breast cancer cells injected into immunocompromised mice metastasize to the spine and if this process is influenced by the amount of trabecular bone. We also took advantage of mice carrying the transgene, which display severe osteoporosis. After crossing this transgene into the immunocompromised NSG background we injected MDA-MB-231-SCP2 breast cancer cells and analyzed their distribution three weeks thereafter. We identified more tumor cells and clusters of different size in spine sections than in femora, which allowed influences on bone remodeling cell types to be analyzed by comparing tumor-free to tumor-burdened areas. Unexpectedly, the transgene did not affect spreading and metastatic outgrowth of MDA-MB-231-SCP2 cells, suggesting that bone tumor interactions are more relevant at later stages of metastatic progression.

Citing Articles

Computed tomography-based structural rigidity analysis can assess tumor- and treatment-induced changes in rat bones with metastatic lesions.

Bohanske M, Momenzadeh K, van der Zwaal P, Hoogwater F, Cory E, Biggane P BMC Cancer. 2024; 24(1):767.

PMID: 38926864 PMC: 11210006. DOI: 10.1186/s12885-024-12374-8.


Animal models of cancer metastasis to the bone.

Yu Y, Li K, Peng Y, Wu W, Chen F, Shao Z Front Oncol. 2023; 13:1165380.

PMID: 37091152 PMC: 10113496. DOI: 10.3389/fonc.2023.1165380.


Muscle and Bone Defects in Metastatic Disease.

Pauk M, Saito H, Hesse E, Taipaleenmaki H Curr Osteoporos Rep. 2022; 20(5):273-289.

PMID: 35994202 PMC: 9522697. DOI: 10.1007/s11914-022-00741-y.

References
1.
Ottewell P, Wang N, Brown H, Fowles C, Croucher P, Eaton C . OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Int J Cancer. 2015; 137(4):968-77. DOI: 10.1002/ijc.29439. View

2.
Riquelme M, Cardenas E, Jiang J . Osteocytes and Bone Metastasis. Front Endocrinol (Lausanne). 2020; 11:567844. PMC: 7591672. DOI: 10.3389/fendo.2020.567844. View

3.
Sethi N, Dai X, Winter C, Kang Y . Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011; 19(2):192-205. PMC: 3040415. DOI: 10.1016/j.ccr.2010.12.022. View

4.
Dabbagh Kakhki V, Anvari K, Sadeghi R, Mahmoudian A, Torabian-Kakhki M . Pattern and distribution of bone metastases in common malignant tumors. Nucl Med Rev Cent East Eur. 2013; 16(2):66-9. DOI: 10.5603/NMR.2013.0037. View

5.
Yin J, Selander K, Chirgwin J, Dallas M, Grubbs B, Wieser R . TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999; 103(2):197-206. PMC: 407876. DOI: 10.1172/JCI3523. View